This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (1)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In a recent issue of the Archives, one notes how the article on the Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study (AFASAK 2) by Gulløv et al¹ and Albers'² editorial conceal the most striking data from AFASAK 2, namely, that warfarin was not statistically significantly superior to aspirin alone for stroke prevention in atrial fibrillation. The cumulative primary event rates were 3.6% with aspirin and 2.8% with adjusted-dose warfarin sodium (P=.67). The introductory dependent clause in the "Conclusions" section of the Gulløv et al abstract— "Although the difference was insignificant . . ." —perhaps should be gist of the final conclusion vis-à-vis AFASAK 2's aspirin vs warfarin. The abstract's "Conclusions" section, however, cloaks the data regarding warfarin vs aspirin alone. No mention at all is made of the above findings. Albers' editorial likewise footnotes his position with no mention, for example, of another important recent meta-analysis about . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

State-of-the-Art Review: Warfarin Therapy: A Review of the Literature Since the Fifth American College of Chest Physicians' Consensus Conference on Antithrombotic Therapy
Lodwick
CLIN APPL THROMB HEMOST 1999;5:208-215.